Vivoryon Therapeutics NV (LTS:0R3M) Buyback Yield %: -14.76 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R3M Vivoryon Therapeutics NV LTS:0R3M
33 GF Score
Price €1.21
! 2 Warning Signs
View Full Analysis

What is Vivoryon Therapeutics NV Buyback Yield %?

Vivoryon Therapeutics NV LTS:0R3M +0.84% 33 Buyback Yield % is -14.76 as of Jul. 21, 2026. GuruFocus rates LTS:0R3M with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 740 Biotechnology companies, Vivoryon Therapeutics NV ranks worse than 60.41% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Vivoryon Therapeutics NV's current buyback yield was -14.76%.

Vivoryon Therapeutics NV Buyback Yield % Related Terms

Vivoryon Therapeutics NV Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Vivoryon Therapeutics NV's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV Buyback Yield % Chart

Vivoryon Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.31 -14.35 -12.40 0.00 -11.81

Vivoryon Therapeutics NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.42 -1.67 0.00 -0.01 -12.06

LTS:0R3M vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Vivoryon Therapeutics NV's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivoryon Therapeutics NV Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Vivoryon Therapeutics NV's Buyback Yield % falls into.


LTS:0R3M
33GF Score
Vivoryon Therapeutics NV LTS:0R3M
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivoryon Therapeutics NV Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Vivoryon Therapeutics NV's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 5.072) / 42.9403
=-11.81%

Vivoryon Therapeutics NV's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 5.072) / 42.9403
=-11.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -14.76 mean?
Vivoryon Therapeutics NV (LTS:0R3M) has a Buyback Yield % of -14.76 as of Jul. 21, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Vivoryon Therapeutics NV and its competitors. According to the industry distribution chart, Vivoryon Therapeutics NV ranks #447 out of 740 companies in the Biotechnology industry, placing it in the top 60.4%.
Is Vivoryon Therapeutics NV's Buyback Yield % too high?
Vivoryon Therapeutics NV's current Buyback Yield % is -14.76. Based on the distribution chart, Vivoryon Therapeutics NV ranks #447 out of 740 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vivoryon Therapeutics NV has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vivoryon Therapeutics NV ranks #447 out of 740 companies for Buyback Yield %. This places Vivoryon Therapeutics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Vivoryon Therapeutics NV and its competitors. Vivoryon Therapeutics NV's current Buyback Yield % is -14.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (LTS:0R3M) has a current Buyback Yield % of -14.76. The current Buyback Yield % is -14.76. Vivoryon Therapeutics NV's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Vivoryon Therapeutics NV (LTS:0R3M), the current Buyback Yield % is -14.76 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivoryon Therapeutics NV Business Description

Address Weinbergweg 22, Halle, SN, DEU, 06120
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
33GF Score

Get the complete analysis for LTS:0R3M

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.21
Price